Single and Multiple Dose Pharmacokinetics of GLPG0634 in Elderly Healthy Subjects
NCT ID: NCT01665924
Last Updated: 2013-03-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
36 participants
INTERVENTIONAL
2012-07-31
2012-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
During the course of the study, the effect of aging on the pharmacokinetics as well as the effects of GLPG0634 on mechanism of action-related parameters in the blood (pharmacodynamics) will be assessed and the safety of multiple oral doses of GLPG0634 in elderly healthy subjects will be characterized.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Investigation of the Pharmacokinetics and Metabolism of GLPG0634 in Healthy Male Subjects
NCT01820806
A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Given by Mouth and Into a Vein as an Injection
NCT03787186
Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes
NCT01686945
A Study in Healthy Male Volunteers to Test How the Test Medicine GLPG1972 is Taken up by the Body When Given by Mouth and Into the Vein as an Injection
NCT04136327
Oral Administration of Peptides; Absorption From Gastrointestinal Tract
NCT00468884
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
40-50 years old
GLPG0634 100mg capsule once a day for 10 days in healthy subjects between 40 and 50 years old
GLPG0634 100mg capsule once a day for 10 days
65-74 years old
GLPG0634 100mg capsule once a day for 10 days in healthy subjects between 65 and 74 years old
GLPG0634 100mg capsule once a day for 10 days
75 years and older
GLPG0634 100mg capsule once a day for 10 days in healthy subjects of 75 years and older
GLPG0634 100mg capsule once a day for 10 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GLPG0634 100mg capsule once a day for 10 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI between 18-30 kg/m2
Exclusion Criteria
* Drug or alcohol abuse
* Smoking
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Galapagos NV
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Frédéric Vanhoutte, MD
Role: STUDY_DIRECTOR
Galapagos NV
Magdalena Petkova, MD
Role: PRINCIPAL_INVESTIGATOR
SGS LSS Clinical Pharmacology Unit Antwerp
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
SGS LSS Clinical Pharmacology Unit Antwerp
Antwerp, Antwerp, Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GLPG0634-CL-104
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.